RESMED, INC.

RMD
Delayed Quote. Delayed  - 08/16 04:00:01 pm
236.1USD -0.43%
Valuation
Fiscal Period: June 2022 2023
Capitalization1 30 69134 571
Enterprise Value (EV)1 31 19234 974
P/E ratio 39,6x38,3x
Yield 0,80%0,77%
Capitalization / Revenue 8,58x8,65x
EV / Revenue 8,72x8,75x
EV / EBITDA 26,8x26,2x
Price to Book 9,35x8,25x
Nbr of stocks (in thousands) 146 405146 425
Reference price (USD) 210236
Announcement Date 08/11/2022-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: June 2022 2023
Net sales1 3 5783 995
EBITDA1 1 1621 333
Operating profit (EBIT)1 1 0001 161
Operating Margin 28,0%29,1%
Pre-Tax Profit (EBT)1 9601 141
Net income1 779911
Net margin 21,8%22,8%
EPS2 5,306,17
Dividend per Share2 1,681,81
Announcement Date 08/11/2022-
Previous period Next period
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: June 2022 2023
Net Debt1 502403
Net Cash position1 --
Leverage (Debt / EBITDA) 0,43x0,30x
Free Cash Flow1 2161 026
ROE (Net Profit / Equities) 27,2%25,6%
Shareholders' equity1 2 8613 556
ROA (Net Profit / Asset) 17,3%16,7%
Assets1 4 5005 438
Book Value Per Share2 22,428,6
Cash Flow per Share2 2,398,13
Capex1 135123
Capex / Sales 3,77%3,08%
Announcement Date 08/11/2022-
Previous period Next period
1 USD in Million
2 USD
Estimates
Financial Ratios
Size 2023e 2024e
Capitalization 34 571 M $ -
Enterprise Value (EV) 34 974 M $ 34 206 M $
Valuation 2023e 2024e
P/E ratio (Price / EPS) 38,3x 33,3x
Capitalization / Revenue 8,65x 7,99x
EV / Revenue 8,75x 8,08x
EV / EBITDA 26,2x 23,5x
Yield (DPS / Price) 0,77% 0,85%
Price to book (Price / BVPS) 8,25x 6,75x
Profitability 2023e 2024e
Operating Margin (EBIT / Sales) 29,1% 30,3%
Operating Leverage (Delta EBIT / Delta Sales) 1,38x 1,57x
Net Margin (Net Profit / Revenue) 22,8% 24,1%
ROA (Net Profit / Asset) 16,7% 17,2%
ROE (Net Profit / Equities) 25,6% 24,9%
Rate of Dividend 29,3% 28,2%
Balance Sheet Analysis 2023e 2024e
CAPEX / Sales   3,08% 3,08%
Cash Flow / CA 29,8% 29,9%
Capital Intensity (Assets / Revenue) 1,36x 1,40x
Financial Leverage (Net Debt / EBITDA) 0,30x -
Price Earning Ratio
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS & Dividend